By NewsDesk  @infectiousdiseasenews

The Swedish Public Health Agency has decided that Janssen’s vaccine, just like AstraZeneca’s vaccine, should only be recommended for people born in 1956 and earlier. This is after blood clots with a low level of platelets were classified as a very rare but serious side effect linked to Janssen’s vaccine against covid-19. The cases of this side effect have mainly been reported among younger people, while the elderly are at a greatly increased risk of dying or suffering from severe covid-19 disease.


The vaccine was to be delivered to Sweden in larger quantities in May. As the vaccine is still not recommended for people under the age of 65, the Swedish Public Health Agency decides to currently recommend a continued break for the use of Janssen’s vaccine in Sweden for all age groups.

We think it is better to recommend the vaccines that healthcare is now used to using. People over the age of 65 will still be able to get vaccines of the other three varieties, says Anders Tegnell, state epidemiologist.

Subscribe to Outbreak News TV

The Swedish Public Health Agency returns with a forecast of how the vaccination work can be affected in connection with the analysis and reporting that takes place every 14 days. Up to and including 22 April, 72 percent of Sweden’s population over the age of 65 had received at least one dose.

J&J COVID-19 vaccine pause lifted after safety review

Poll Shows Oral COVID-19 Pill Option Could Overcome Resistance to Injectable Vaccine

CDC: Pause the use of the J&J COVID-19 vaccine until reviewed

AstraZeneca’s Vaxzevria: European officials find blood clots should be listed as very rare side effect

Canada: AstraZeneca COVID-19 vaccine should not be used in adults under 55 years of age at this time

Sweden: Astra Zeneca’s vaccine can continue for people aged 65 and over